Esomok-D 40 Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed to manage gastrointestinal disorders characterized by acid reflux, dyspepsia, and delayed gastric emptying. Esomeprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby providing symptomatic relief and promoting mucosal healing in conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by accelerating gastric emptying and improving esophageal sphincter tone, which helps alleviate nausea, vomiting, and bloating associated with delayed gastric emptying or gastroparesis. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing patient compliance and efficacy. Esomok-D 40 Capsule SR is indicated for patients requiring combined acid suppression and prokinetic therapy. It should be used under medical supervision, considering contraindications such as known hypersensitivity, cardiac arrhythmias, or concurrent use of QT-prolonging drugs. Monitoring is advised in patients with hepatic impairment or those on concomitant medications that may interact with either component. This combination offers a comprehensive approach to managing upper gastrointestinal motility and acid-related disorders.